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womeNS’ health
plants have formed an integral part of our existence since time immemorial and since then we have been using them in many forms to support our survival.  The use of plants or 
plant extracts for medicinal purposes has also been extensively 
explored and the intricacy of this research has followed the 
vertiginous progress in diagnostics and intervention.  The use of 
synthetic chemicals for the cure of disease has nowadays taken 
up much of the pharmaceutical field; despite this, herbalism, or 
the study and use of plants as medicinals, is still a thriving facet 
of the pharma industry.
One of the medical fields in which herbalism is trying 
to establish a valid market is gynaecology, more specifically 
the menopause.  Menopause is a highly particular phase in 
a woman’s life that marks the end of fertility and slowly but 
determinedly steers her into middle and old age.  It is a time 
of great physiological and psychological change which, if not 
tackled well, could lead to deleterious repercussions in both 
aspects.  The hallmark of this biological havoc is a progressive 
decrease in the production of oestrogen by the ovaries which, if 
not corrected, could result in day-to-day inconveniences such 
as hot flushes, vaginal dryness, sleeping problems and mood 
swings to more serious consequences like osteoporosis and 
cardiovascular disease. 
Replacing the depleted oestrogen is a natural solution to 
this predicament.  For many decades, in fact, the rationale of 
the treatment for menopausal symptoms has hinged around 
oestrogen replacement, what is more commonly described 
as HRT or hormone replacement therapy, in the form of oral 
tablets, slow release subcutaneous administrations or local 
creams for vaginal dryness.  Although their efficacy is close 
to optimal, even where the irritating day-to-day symptoms 
are concerned, the adverse events they can create can be quite 
hazardous especially where heart    disease and breast cancer in 
susceptible individuals are concerned.
Complementary alternative medicines or CAMs have been 
a popular alternative or additive1, especially in the United 
States2,3, where at least 40% of the population uses a CAM at any 
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one time or the other, with women over the age of 40 being the 
most avid users4.  The publication of the results of the Women’s 
Health Initiative randomised controlled trial in 20025, which 
highlighted a negative benefit-risk ratio with the prolonged use 
(5.2 years) of hormone therapy in older postmenopausal women 
also shifted the onus of popularity on the ‘alternatives’.  The 
CAMs most commonly used are herbal remedies and dietary 
phytoestrogens.
Herbal remedies come in various forms, including black 
cohosh, dong quai, ginseng, red clover and evening primrose 
oil.  The most popular and the most studied herb is black cohosh 
whose medicinal use in gynaecology dates back to the Native 
Americans.  Some clinical studies have found it effective in the 
treatment of hot flushes; however none of these trials have lasted 
more than six months and thus its efficacy in the long term 
is questionable2. Other clinical trials found no benefits when 
compared to placebo and in one trial6, black cohosh appeared 
to be mostly effective in a subset of women with recent onset of 
menopause3.
The identity of the active compounds of black cohosh are 
still unknown, and this  presents an uncertainty both about its 
mode of action and its safety profile.  Sadly, this is the dilemma 
faced with a number of herbal remedies launched on the market. 
The fact that most of the clinical trials are not placebo-controlled 
and only span a short period of time does nothing to help the 
situation2.
Dietary phytoestrogens, extracted from a variety of food 
plants such as soy, beans and clover, are another alternative in 
the natural remedy repertoire.  Interest in these products was 
sparked when high dietary intakes of soy was postulated to be 
one of the reasons of low incidence of menopausal symptoms 
in Japan, China and Korea.  Composed of phenolic (rather than 
steroidal) compounds, these substances include chemicals such 
as isoflavones which when acted on by intestinal bacteria are       
converted from the conjugated to the unconjugated active forms 
such as genistein, daidzein and equol2.  
The mode of action of the isoflavones is clearer than their 
herbal counterparts.  The oestrogen receptor is particular 
amongst the other steroid receptors in that it has the ability 
to bind with a wide range of molecules.  It is made up of an α 
and a β counterpart - the α part of the receptor is responsible 
for breast and uterus while the β aspect controls bone, blood 
vessels and the brain (figure 1). The 17-β oestradiol molecule 
found in hormone replacement therapy is non-selective and 
this in fact results in the deleterious cardiac, uterine or breast 
side effects in susceptible individuals.  Isoflavones, on the other 
hand have more affinity for the β-part of the receptor and thus 
is more selective to vasomotor, psychological and osteoporotic 
symptomatology7.
Despite their promising mode of action, the niche for the 
isoflavone market seems to focus mostly on the vasomotor 
symptoms of menopause.  11 clinical trials have examined 
the use of isoflavones for hot flushes2; of these, only 3 out of 8 
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studies lasted more than 6 weeks and no particular efficacy was 
found even when used in moderately long term (24 weeks).  
Comparisons were not possible due to the different product, 
dosage and scoring systems used and the same beneficial effects 
were found both in the study and the placebo groups2. On the 
other hand, recent placebo-controlled double-blind studies 
showed promising results8, and a 2012 systematic   review and 
meta-analysis of randomized controlled trials concluded that 
soy isoflavone supplements are significantly more effective than 
placebo in the reduction of hot flashes.9
Omega-3-fatty acids have also been considered as a 
treatment for hot flushes and psychological distress, especially 
considering their recommendable safety profile and known 
beneficial cardiovascular effects3.  Even if studies so far, have 
been encouraging10, their role in menopausal women without 
overt psychological symptoms is still unknown.
Considering their popularity and widespread use, it is 
clear that despite their hazy clinical profile, complementary 
alternative medicines have found their place in the menopause 
community. I believe that better planned clinical trials with 
a larger number of participants and taking place over more 
extended timelines could yield more scientifically coherent 
data which would certainly support more their acceptance in 
the clinical scenario.  After all, complementary, alternative or 
otherwise, harmonisation and standardisation of marketing 
protocols for all medicinals is the best way forward to 
transparency and accountability in the pharma industry. 
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